Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders ...

As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly (NYSE: LLY) is ...

Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Eli Lilly is doubling down on manufacturing investments announcing a US3 billion expansion of its Wisconsin facility ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...

Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha ...

Regulators approved Wegovy in 2021. Both drugs are different versions of the diabetes treatments Mounjaro and Ozempic from Lilly and Novo, respectively. Shares of Eli Lilly and Co., based in ...